Allergan assuages shareholder fears over losing Restasis patent

(Reuters) - Allergan Plc on Wednesday reassured shareholders that it would return to earnings growth in 2019 after losing a major patent ruling last month on its second-most important drug, dry-eye treatment Restasis.